Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide Gas Inhalation Therapy in Mild/Moderate COVID-19
NCT04305457Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2020
- Primary completion
- Aug 2023
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nitric oxide in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Number of Participants With Mild/Moderate COVID-19 Requiring Intubation and Mechanical Ventilation at 28 days. Started Mar 2020; status: terminated.
02
Drugs
nitric oxide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04305457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305457.